

Program of Medical Genetics for Medicine students (SUN 2013-2014)

Prof. Sandro Banfi – Vincenzo Nigro

1. • The human genome: genes and organization
2. • Next generation sequencing (NGS), the exome
3. • Penetrance and expressivity, anticipation
4. • Homozygosity and compound heterozygosity
5. • Haploinsufficiency, congenital and syndromic disorders
6. • Mechanism of splicing and its alterations
7. • Classes of point mutations, transition and transversion, conservative, missense, nonsense, nonstop
8. • Insertions, deletions and frame-shift and non-duplication, gene conversion
9. • Pathological significance of the various classes of DNA variations
10. • International Nomenclature of genetic variation and significance of reporting
11. • Genetic counseling: reproductive risk
12. • Prenatal diagnosis and presymptomatic testing
13. • Karyotype analysis, the FISH
14. • Molecular karyotyping by arrayCGH

Program of Medical Genetics for Medicine students part 2

15. Aneuploidy in abortions and risk of recurrence
16. Triploidy, tetraploidy
17. The X chromosome inactivation and PAR
18. Autosomal trisomies
19. Sex chromosome trisomies
20. Monosomies, Turner syndrome
21. Chromosomal deletions, paracentric and pericentric inversions
22. Balanced and unbalanced translocations, Robertsonian, chromosomal markers
23. Submicroscopic deletions and duplications (Williams s., diGeorge, Cri du Chat, Smith-Magenis)
24. Monoallelic Mendelian disorders with de novo mutations (craniosynostosis, achondroplasia)
25. Autosomal dominant Mendelian disorders (neurofibromatosis, Marfan, polycystic kidney disease)
26. X-Linked disorders (Duchenne and Becker muscular dystrophy, hemophilia, X-linked mental retardation, Rett syndrome)

Program of Medical Genetics for Medicine students part 3

27. Autosomal recessive disorder (cystic fibrosis, alpha and beta thalassemia, spinal muscular atrophy, hemochromatosis, glycogen storage disorders, lysosomal storage disorders)
28. Mendelian disorders with genetic heterogeneity (limb-girdle muscular dystrophies, retinitis pigmentosa)
29. Dynamic mutations in non-coding regions (fragile X, myotonic dystrophy) and coding regions (Huntington's disease, spinocerebellar ataxias)
30. Mutations in chromosomal regions with imprinting (Prader-Willi syndrome, Angelman syndrome, Beckwith-Wiedemann syndrome, Silver-Russell), uniparental disomy
31. Mutations of mitochondrial DNA (MERFF, MELAS, LHON, KS, Leigh syndrome)
32. Genetic predisposition
33. Multifactorial traits
34. GWAS studies
35. microRNA function and role in genetic diseases
36. General principles of advanced therapies for genetic diseases

REFERENCE TEXTBOOKS:

- Tom Strachan, Andrew Read. Human Molecular Genetics, 4th edition. Garland Science
- Thompson and Thompson Genetics in Medicine. Saunders 7th edition

ORAL EXAM

1953

Genome

1953






- The first Polymerase chain reaction is assembled in 1985
- The Human Genome Project starts in 1985
- the entire sequencing of the human genome was completed in 2001 by two competing groups




2001

Classes of interspersed repeat in the human genome





			Length	Copy number	Fraction of genome
LINEs	Autonomous		6–8 kb	850,000	21%
	Non-autonomous		100–300 bp		
Retrovirus-like elements	Autonomous		6–11 kb	450,000	8%
	Non-autonomous		1.5–3 kb		
DNA transposon fossils	Autonomous		2–3 kb	300,000	3%
	Non-autonomous		80–3,000 bp		

Almost all transposable elements fall into one of four types:


- ❖ Long interspersed elements (LINEs)
- ❖ Short interspersed elements (SINEs)
- ❖ LTR retrotransposons
- ❖ DNA transposons




Red bar = interspersed repeats, blue = exons




1	245,203,898	218,712,898
2	243,315,028	237,043,673
3	199,411,731	193,607,218
4	191,610,523	186,580,523
5	180,967,295	177,524,972
6	170,740,541	166,880,540
7	158,431,299	154,546,299
8	145,908,738	141,694,337
9	134,505,819	115,187,714
10	135,480,874	130,710,865
11	134,978,784	130,709,420
12	133,464,434	129,328,332
13	114,151,656	95,511,656
14	105,311,216	87,191,216
15	100,114,055	81,117,055
16	89,995,999	79,890,791
17	81,691,216	77,480,855
18	77,753,510	74,534,531
19	63,790,860	55,780,860
20	63,644,868	59,424,990
21	46,976,537	33,924,742
22	49,476,972	34,352,051
X	152,634,166	147,686,664
Y	50,961,097	22,761,097





conserved segments in the human and mouse genome




the human chromosome have the color of the corresponding regions in mouse chromosomes



Sequence Comparisons Human Chromosome 21 and its Mouse Homologues






KEY
■ Centromere ■ rDNA ■ Constitutive heterochromatin

CCDS IDs per chromosome	
Chromosome	Count
1	2,513
2	1,548
3	1,299
4	898
5	1,028
6	1,236
7	1,094
8	807
9	921
10	971
11	1,509
12	1,240
13	385
14	749
15	711
16	967
17	1,370
18	350
19	1,616
20	672
21	282
22	530
X	967
Y	53
XY	23


UCSC Genome Browser






Frederick Sanger
Nobel price 1958 and 1980
born August 13 1918, died
November 19 2013

History and present: Sanger sequencing



dideoxynucleotide (ddNTP)




deoxynucleotide (dNTP)

ddNTPs (ddATP, ddTTP, ddGTP, ddCTP) are terminators : they block the polymerization of DNA when inserted



flow cell



Solid-phase amplification generates up to 2,000 M of clusters (Illumina HiSeq)



flow cell



Bridge PCR

illumina®

Whole Genome Seq

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE


Whole-Genome Sequencing in a Patient with Charcot–Marie–Tooth Neuropathy

James R. Lupski, M.D., Ph.D., Jeffrey G. Reid, Ph.D., Claudia Gonzaga-Jauregui, B.S.,
David Rio Deiros, B.S., David C.Y. Chen, M.Sc., Lynne Nazareth, Ph.D.,
Matthew Bainbridge, M.Sc., Huyen Dinh, B.S., Chyn Jing, M.Sc.,
David A. Wheeler, Ph.D., Amy L. McGuire, J.D., Ph.D., Feng Zhang, Ph.D.,
Pawel Stankiewicz, M.D., Ph.D., John J. Halperin, M.D., Chengyong Yang, Ph.D.,
Curtis Gehman, Ph.D., Danwei Guo, M.Sc., Rola K. Irikat, B.S., Warren Tom, B.S.,
Nick J. Fantin, B.S., Donna M. Muzny, M.Sc., and Richard A. Gibbs, Ph.D.

ABSTRACT

GENETIC VARIATION IN HUMANS


Variation is measured by single nucleotide polymorphisms (SNPs).




SNPs


single nucleotide polymorphisms

- Natural sequence variation occurs between any two copies of the human genome.
- Most variations are SNPs involving single base substitutions — the rest are insertions or deletions
- A SNP is detected by sequencing a particular region from different individuals, who may have identical (homozygous; T/T or C/C) or different (heterozygous; T/C) bases at the polymorphic site



Single nucleotide substitutions






Mutations observed

T>A or G , C>G or A
G>T or C , A>T or G

transversions



transitions


T>C, C>T, G>A, A>G

46,000

SNPs

T/A, C/G
T/G, C/A

transversions




transitions

T/C, A/G

12,000,000



Expected

transversions




transitions

the most common mutation mechanism




DNA sequence variants




AAA	22.2	Lys	CCA	14.6	Pro	AGA	9.9	Arg	CUC	19.9	Leu
AAG	34.9		CCC	20.0		AGG	11.1		CUU	10.7	
AAC	22.6	Asn	CCG	6.6		CGA	5.4		CUA	6.2	
AAU	16.6		CCU	15.5		CGG	10.4		CUG	42.5	
CAA	11.1	Gln	GCA	14.0	Ala	CGC	11.3	UUA	5.3		
CAG	33.6		GCC	29.1		CGU	4.7	UUG	11.0		
CAC	14.2	His	GCG	7.2		GGA	17.1	Phe	UUC	22.6	
CAU	9.3		GCU	19.6		GGC	25.4		UUU	15.8	
GAA	26.8	Glu	UCA	9.3	Gly	GGU	17.3	Val	GUU	5.9	
GAG	41.4		UCC	17.7		GGC	11.2		GUC	16.3	
GAC	29.0	Asp	UCG	4.2		UGU	14.5		Cys	GUG	30.9
GAU	21.7		UCU	13.2		UGG	9.9			GUU	10.4
UAC	18.8	Tyr	AGC	18.7	Trp	UUA	5.8	Ile			
UAU	12.5		AGU	9.4		AUC	24.3				
ACA	14.4	Thr				Met	AUU		14.9		
ACC	23.0						AUG		22.3		
ACG	6.7										
ACU	12.7										

Key:

- N Nondegenerate site
- N Twofold degenerate site
- N Fourfold degenerate site




Exonic part



Total ~ 3,1 Gbases

Genes with mutations causing human disorders



Total ~ 22,000 genes

HEALTH-2007-1.2-6: High throughput molecular diagnostics in individual patients for genetic diseases with heterogeneous clinical presentation




Heterogeneous genetic disorders can either be caused

- by many different mutations in a single gene (allelic heterogeneity)
- by mutations in different genes (locus heterogeneity)

What is a mutation?

A variation of the DNA sequence


- that is only found in affected individuals
- that is never found in non affected individuals
- that accounts for the pathological process/status
- that, when corrected in time, disease is rescued

Marriage/partnership	
Divorce/separation	
Where the partners are blood relatives (consanguineous relationship)	
Children/siblings	
Identical twins (monozygotic)	
Non-identical twins (dizygotic)	

	Male	Female	Sex Unknown
Individual			
Affected individual (symbol coloured in)			
Multiple Individuals			
Deceased			
Pregnancy (the unborn baby of a pregnant mother)			
Miscarriage			
Person providing pedigree information			

..that is only found in affected and that is never found
in non affected

incomplete penetrance




that is more often found in affected
than in non affected...


1-allele diseases

- monoallelic mutations may be responsible for **dominant** or **X-linked** disorders
- new **random** mutations are the rule with an unpredictable pattern of distribution

relative frequency of *de novo* achondroplasia for different paternal ages




relative frequency of *de novo* neurofibromatosis for different paternal ages




the number of male germ-cell divisions

Age	Chromosome replications
15	35
20	150
30	380
40	610
50	840

All trisomies



X-linked disorders



- **DMD Duchenne Muscular Dystrophy**

- **1/3,500 boys**

- Onset** -- Early childhood - about 2 to 6 years

- **Laboratory** -- CK (50x to 1.000x), LDH5, ALT, AST, aldolase increase

- Symptoms** -- Generalized weakness and muscle wasting affecting proximal limb muscles first. Calves often enlarged. Heart involvement

- Progression** -- Disease progresses slowly but will affect all voluntary muscles. Survival possible beyond late twenties

- **BMD Becker Muscular Dystrophy**


- **1/10,000 boys**

- Onset** -- Adolescence or adulthood


- Symptoms** -- Almost identical to Duchenne but often much less severe. Heart involvement

- Progression** -- Slower and more variable than DMD with survival well into mid to late adulthood


Normal




Mild BMD




Severe BMD




Manifesting carrier of DMD




Revertant fibres in a patient with IMD




DMD




(A) Less than 10 kb






(B) Less than 100 kb




(C) More than 100 kb



DMD gene is the largest of the human genome encompassing 2.22 Mb on the short arm of the X-chromosome







2-allele diseases

- novel mutations are rare, usually mutations have a long history (100-1,000 generations)
- mutations have an **ethnic signature** with a predictable pattern of distribution and frequency in specific geographic areas
- biallelic mutations may be responsible for **autosomal recessive** disorders
- polymorphisms and private variants may be more easily discriminated vs true mutations


Worldwide distribution of α - and β -thalassemias



Weatherall DJ *Nat Rev Genetics* 2:245, 2001



2-allele diseases

A




high carrier frequency
is a risk factor for
compound heterozygosity

B



consanguineity is a risk factor for
homozygosity, even if disease alleles
are very rare

The Human Gene Mutation Database (HGMD)



67030 mutations in 2478 genes

five effects of a mutated allele

null or amorph
no product/
no activity

hypomorph
reduced amount /
activity

usually
recessive

hypermorph
increased amount /
activity


neomorph
new product /
new activity

usually
dominant


antimorph
antagonistic product /
activity

usually
dominant

With an amorph or hypomorph heterozygous allele, why the phenotype may be also dominant?



dominant loss of function mutations in the PAX3 gene
(Waardenburg syndrome)
haploinsufficiency



Structural genomic variants

unbalanced forms of
variation (copy-number
variation)

- deletions
- duplications
- insertions

balanced forms

- inversions
- translocations

they are the most difficult to interpret with respect
to their functional consequences

Structural genomic variants

at least 50 base pairs (bp) in size

- usually heterozygous
- high locus-specific formation rates
- 0.5–1% sequence differences between individuals

new technologies

- microarray based comparative genome hybridization (array CGH)
- high-throughput paired-end DNA next-generation sequencing

in the Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources (**DECIPHER**) 20% of disorders are caused by duplications and 80% by deletions

Phenotype/gene dosage correlation

duplications

- result in a 3:2 variant-to-normal gene dosage ratio
- duplications are usually associated with a less-severe phenotype grading than deletions

deletions


- result in a 1:2 variant-to-normal gene dosage ratio
- unmask recessive alleles on the other chromosome
- expose inactive imprinted genes
- result in **haploinsufficiency**




Humans have two copies of most genes, one from the mother and one from the father. This provides a back-up copy, should one copy be lost through mutation



For at least 300 genes, one functional copy is not enough to sustain normal human function, and mutations causing the loss of function of one of the copies of such genes are a major cause of childhood developmental diseases



Williams Syndrome




Typical deletion (~1.5 Mb)




Our patient




Williams s.
FISH : heterozygous deletion 7q11.23



Carrier of a balanced reciprocal X-autosome translocation





cytogenetics



Potassium chloride
hyposmotic
20 min


Centrifugation



Nomenclatura

ISCN

International
System for human
Cytogenetics
Nomenclature







G banding

Procedure

the chromosomes are subjected to controlled digestion with trypsin before staining with Giemsa, a DNA-binding chemical dye

Banding pattern
dark bands are known as G bands, pale bands are G negative







CCDS IDs per chromosome	
Chromosome	Count
1	2,513
2	1,548
3	1,299
4	898
5	1,028
6	1,236
7	1,094
8	807
9	921
10	971
11	1,509
12	1,240
13	385
14	749
15	711
16	967
17	1,370
18	350
19	1,616
20	672
21	282
22	530
X	967
Y	53
XY	23

Analysis

Microscopy



Photograph and karyotype



Karyotype

Metaphase under the microscope




9/11
cytogenetics



9/11 NGS



Origin of the extra
chromosome 21
in 510 families
with free trisomy 21



Data from the Antonarakis and Hassold laboratories


Chromosomal Abnormalities in Down Syndrome

- ◆ Most common chromosomal abnormality
- ◆ 1 in 700 live births



trisomy 21 Down s

Trisomy 21
47,XX,+21




70%
pregnancy
loss

Years	Months											
	0	1	2	3	4	5	6	7	8	9	10	11
25	1376	1372	1367	1363	1358	1353	1348	1343	1338	1333	1328	1322
26	1317	1311	1306	1300	1294	1289	1283	1277	1271	1264	1258	1252
27	1245	1239	1232	1225	1219	1212	1205	1198	1191	1183	1176	1169
28	1161	1154	1146	1138	1130	1123	1115	1107	1099	1090	1082	1074
29	1065	1057	1048	1040	1031	1022	1014	1005	996	987	978	969
30	960	951	942	932	923	914	905	895	886	877	867	858
31	848	839	829	820	810	801	791	782	772	763	753	744
32	734	725	716	706	697	687	678	669	660	650	641	632
33	623	614	605	596	587	578	570	561	552	544	535	527
34	518	510	502	494	486	478	470	462	454	446	439	431
35	424	416	409	402	395	387	381	374	367	360	354	347
36	341	334	328	322	316	310	304	298	292	287	281	275
37	270	265	259	254	249	244	239	235	230	225	221	216
38	212	207	203	199	195	191	187	183	179	175	171	168
39	164	161	157	154	151	147	144	141	138	135	132	129
40	126	124	121	118	116	113	111	108	106	103	101	99
41	97	94	92	90	88	86	84	82	81	79	77	75
42	73	72	70	69	67	65	64	63	61	60	58	57
43	56	54	53	52	51	49	48	47	46	45	44	43
44	42	41	40	39	38	37	36	35	35	34	33	32
45	31	31	30	29	29	28	27	27	26	25	25	24

Risk of 1/239 having a child with Down s.

age	Frequency (live births)
< 35	< 0.3 %
37	0.5 %
40	1 %
50	10 %





40,000 in Italy

Phenotype	%
------------------	----------

Neurological :	
Mental retardation	100
Alzheimer disease	100
	over 35

Muscle :	
Hypotonia	100

Growth :	
Short stature	70


Head :	
Brachycephaly	75

Eyes :	
Epicanthic folds	60
Iris Brushfield spots	55


Mouth :	
Protruding tongue	45

Ears :	
Folded/dysplastic ear	50






Phenotype	%
Limbs :	
Short, broad hands	65
Short 5th finger	60
Skin :	
Characteristic dermatoglyphics	85
Cardiac :	
Congenital heart defect	40
Atrioventricular canal	16
Gastrointestinal abnormalities :	
Duodenal stenosis/atresia	250x
Imperforate anus	50x
Hirschsprung disease	300x
Blood :	
Acute megakaryocytic leukemia 200-400x	
Leukemia (both ALL and AML)	10-20x



Models for the Pathogenesis of Down Syndrome




Gene Expression threshold hypothesis for the Pathogenesis of Down Syndrome

Trisomy 21, 18, 13 screening



Trisomy 21 (Down syndrome)



Trisomy 18 (Edwards syndrome)



Trisomy 13 (Patau syndrome)

Classical Down syndrome screening

NT (mm)

PAPP-A (MoM)

B-HCG (MoM)

Normal : 2.0

Normal : 1.0

Normal : 1.0

T21 : 3.4

T21 : 0.5

T21 : 2.0

T18 : 5.5

T18 : 0.2

T18 : 0.2

T13 : 4.0

T13 : 0.3

T13 : 0.5

NIPT


NON – INVASIVE PRENATAL TESTING

Testing of cff DNA (cell free fetal DNA)

**From maternal blood during pregnancy
starting from 10 weeks**

Useful for trisomies 13, 18 ,21

Cell Free Fetal DNA (cff DNA) in Maternal Blood



DNA SEQUENCING USING CELL FREE DNA

Fetal DNA fragments in maternal blood.



CELL-FREE DNA IN PATIENT PLASMA

```
CCCTTAGCGCTTTAACGTACGTAAAACCTT
AACGTACGTAAAAACGGGGTCAAAGTTCC
GACTTAAATCGGAATCGATGCCAAACTT
GAATCGATGCCCAAACGGGGTCAAAGTTCC
```

MASSIVELY PARALLEL SEQUENCING

CELL-FREE DNA SEQUENCED VIA MPS


Cell free DNA fragments are then sequenced.

Compare the individual sequenced chromosomes against a reference for analysis.



ALIGNMENT OF READS

importance of fetal fraction



Fetal Fraction	Expected ratio for Trisomy
4%	1.02
10%	1.05
20%	1.10
40%	1.20


NIPT cff DNA

< 1 % of total DNA in maternal circulation is fetal

5-30 % of cell-free DNA in maternal circulation is fetal

NIPT measures the ratio of chromosome 21 sequence versus control chromosome sequence to exclude trisomy 21

NIPT cffDNA



Sensitivity NIPT for T21, T18, T13

Sensitivity

T21 : 99.5 %

T18 : 98 %

T13 : 90 %

False-negatives

If NIPT is normal, the residual risk for

trisomy 21, 18, 13 : $< 1 / 10.000$

Specificity NIPT for T21, T18, T13

Specificity

T21 > 99.9 %

T18 > 99.9 %

T13 > 99.9 %

False-positives

**If NIPT is abnormal, the risk that the fetus
has no trisomy 21, 18, 13 :**

small (high risk population)

? (low risk population)

NO NIPT for sex aneuploidies

- Phenotype for sex aneuploidies is highly variable
- Mosaicism in the fetus is a problem
- Mosaicism in the mother is a problem
- NIPT for sex aneuploidies is less accurate

NIPT Indications

NIPT is the test of choice when there is :

- Increased maternal age
- Increased risk on Combination or triple test
- Anxiety for invasive procedure (AC / CVS)

NIPT Contra indications

NIPT is NOT the test of choice when there is :

- Fetal anomalies on ultrasound
- A triplet pregnancy
- Vanished twin
- Known genetic anomalies that cannot be diagnosed by NIPT

NIPT Advantages versus combi test with AC / CVS

- High sensitivity (few false-negatives)
- High specificity (few false-positives)
- More than T21
- Non-invasive : no fetal risk
 - CVS : Risk of miscarriage : 1-2 %
 - AC : Risk of miscarriage : 0.5 %

NIPT Disadvantages

- Expensive (690 Euro)
 - Combi test : 150 Euro
 - Combitest + AC + karyotype : 1000 Euro ?
- Only testing 3 chromosomes, and gender
- Failure rate (after 1 or 2 tests): < 1 %
- Specific kits
- Not available everywhere

Companies offering NIPT

- **ARIOSA (US)**
- **VERINATA (US)**
- **NATERA (US)**
- **SEQUENOM (US)**
- **BGI (China)**
- **LIFE-CODEXX (Germany)**

NIPT results

- 1. Normal result :** no specific follow up necessary, unless ultrasound examination of the fetus reveals anomalies
- 2. Test failure :** in 3 % pregnancies not enough fetal DNA : NIPT repeated at no extra cost.
- 3. Abnormal NIPT result :** amniocentesis or chorion biopsy

NIPT failures

If less than 4 % of cf DNA is fetal

1. High amounts of maternal cf DNA :

Maternal obesity

2. Low amounts of fetal cf DNA :

- **Trisomy 18**
- **Triploidy ??**

NIPT versus classical Down syndrome screening

	Classical	NIPT
False negatives	30 - 40 %	0.3 %
False positives	5 % (> 95 % of positives)	< 0.1 % (?)
Result	> Week 13	> Week 12
Price	150 euro	590 Euro

NIPT versus classical screening in a country with 10 million inhabitants

	Classical	NIPT
Number screenings	100.000	100.000
Expected T21	200 (1/500)	200 (1/500)
Detection rate	73 %	< 99 %
T21	146	199
False-negatives	54 (27 %)	< 1 (0.3 %)
False-positives	4990 (4.8 %)	< 100 (0.03 %)
Iatrogenic Miscarriage	50	1

NIPT : the future

1. Array CGH

- All chromosomes
- Small deletions - duplications

2. Detection common monogenic mutations

- CF

3. Whole exome / genome sequencing